296 related articles for article (PubMed ID: 24393391)
1. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses.
Park BJ; Cha MK; Kim IH
BMC Res Notes; 2014 Jan; 7():7. PubMed ID: 24393391
[TBL] [Abstract][Full Text] [Related]
2. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
Chen C; Chen Q; Dong Y; Liu X
Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
[TBL] [Abstract][Full Text] [Related]
3. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
[TBL] [Abstract][Full Text] [Related]
4. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
5. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
7. The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer.
Lee YJ; Kim Y; Choi BB; Kim JR; Ko HM; Suh KH; Lee JS
BMC Cancer; 2022 Jan; 22(1):12. PubMed ID: 34979986
[TBL] [Abstract][Full Text] [Related]
8. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer.
Wang G; Qin Y; Zhang J; Zhao J; Liang Y; Zhang Z; Qin M; Sun Y
Int J Mol Sci; 2014 May; 15(6):9546-65. PubMed ID: 24879526
[TBL] [Abstract][Full Text] [Related]
9. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
El-Attar NI; Gaefar HA
Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
[TBL] [Abstract][Full Text] [Related]
10. Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer.
Kulasingam V; Zheng Y; Soosaipillai A; Leon AE; Gion M; Diamandis EP
Int J Cancer; 2009 Jul; 125(1):9-14. PubMed ID: 19322904
[TBL] [Abstract][Full Text] [Related]
11. FTO, PIK3CB serve as potential markers to complement CEA and CA15-3 for the diagnosis of breast cancer.
Mi J; Zhang H; Cao W; Yuan C
Medicine (Baltimore); 2023 Oct; 102(42):e35361. PubMed ID: 37861518
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
Fan J; Yu H; Lv Y; Yin L
Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
[TBL] [Abstract][Full Text] [Related]
13. Thioredoxin 1 as a serum marker for ovarian cancer and its use in combination with CA125 for improving the sensitivity of ovarian cancer diagnoses.
Park BJ; Cha MK; Kim IH
Biomarkers; 2014 Nov; 19(7):604-10. PubMed ID: 25174623
[TBL] [Abstract][Full Text] [Related]
14. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.
Arslan N; Serdar M; Deveci S; Ozturk B; Narin Y; Ilgan S; Ozturk E; Ozguven MA
Ann Nucl Med; 2000 Oct; 14(5):395-9. PubMed ID: 11108173
[TBL] [Abstract][Full Text] [Related]
15. Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients.
Bahrami A; Mortazavizadeh MR; Yazdi MF; Chamani M
East Mediterr Health J; 2012 Oct; 18(10):1055-9. PubMed ID: 23301361
[TBL] [Abstract][Full Text] [Related]
16. [Preoperative serum CA15.3 and CEA levels and clinical-biological parameters in breast tumors].
Ruibal A; Garrido Pumar M; Arias JI
Rev Esp Med Nucl; 2006; 25(3):180-3. PubMed ID: 16762272
[TBL] [Abstract][Full Text] [Related]
17. The role of TPS, CA125, CA15-3 and CEA in prediction of distant metastasis of breast cancer.
Zhang J; Wei Q; Dong D; Ren L
Clin Chim Acta; 2021 Dec; 523():19-25. PubMed ID: 34454906
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
Nicolini A; Colombini C; Luciani L; Carpi A; Giuliani L
Br J Cancer; 1991 Jul; 64(1):154-8. PubMed ID: 1854615
[TBL] [Abstract][Full Text] [Related]
19. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
Shao Y; Sun X; He Y; Liu C; Liu H
PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
[TBL] [Abstract][Full Text] [Related]
20. Comparison of serum CA15-3 and CEA in breast cancer.
Hou MF; Huang TJ; Hsieh JS; Huang YS; Huang CJ; Chan HM; Wang JY; Chen YL; Jong SB; Yang CC
Gaoxiong Yi Xue Ke Xue Za Zhi; 1995 Dec; 11(12):660-6. PubMed ID: 8551526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]